FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017024085> ?p ?o ?g. }

• W2017024085 endingPage "1204" @default.
• W2017024085 startingPage "1198" @default.
• W2017024085 abstract "Purpose To test whether pharmacologic inhibition of ribonucleotide reductase (RNR) by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) enhances radiation sensitivity during low-dose-rate ionizing radiation provided by a novel purpose-built iridium-192 cell irradiator. Methods and Materials The cells were exposed to low-dose-rate radiation (11, 23, 37, 67 cGy/h) using a custom-fabricated cell irradiator or to high-dose-rate radiation (330 cGy/min) using a conventional cell irradiator. The radiation sensitivity of human cervical (CaSki, C33-a) cancer cells with or without RNR inhibition by 3-AP was evaluated using a clonogenic survival and an RNR activity assay. Alteration in the cell cycle distribution was monitored using flow cytometry. Results Increasing radiation sensitivity of both CaSki and C33-a cells was observed with the incremental increase in radiation dose rates. 3-AP treatment led to enhanced radiation sensitivity in both cell lines, eliminating differences in cell cytotoxicity from the radiation dose rate. RNR blockade by 3-AP during low-dose-rate irradiation was associated with low RNR activity and extended G1-phase cell cycle arrest. Conclusions We conclude that RNR inhibition by 3-AP impedes DNA damage repair mechanisms that rely on deoxyribonucleotide production and thereby increases radiation sensitivity of human cervical cancers to low-dose-rate radiation. To test whether pharmacologic inhibition of ribonucleotide reductase (RNR) by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) enhances radiation sensitivity during low-dose-rate ionizing radiation provided by a novel purpose-built iridium-192 cell irradiator. The cells were exposed to low-dose-rate radiation (11, 23, 37, 67 cGy/h) using a custom-fabricated cell irradiator or to high-dose-rate radiation (330 cGy/min) using a conventional cell irradiator. The radiation sensitivity of human cervical (CaSki, C33-a) cancer cells with or without RNR inhibition by 3-AP was evaluated using a clonogenic survival and an RNR activity assay. Alteration in the cell cycle distribution was monitored using flow cytometry. Increasing radiation sensitivity of both CaSki and C33-a cells was observed with the incremental increase in radiation dose rates. 3-AP treatment led to enhanced radiation sensitivity in both cell lines, eliminating differences in cell cytotoxicity from the radiation dose rate. RNR blockade by 3-AP during low-dose-rate irradiation was associated with low RNR activity and extended G1-phase cell cycle arrest. We conclude that RNR inhibition by 3-AP impedes DNA damage repair mechanisms that rely on deoxyribonucleotide production and thereby increases radiation sensitivity of human cervical cancers to low-dose-rate radiation." @default.
• W2017024085 created "2016-06-24" @default.
• W2017024085 creator A5016353084 @default.
• W2017024085 creator A5042269391 @default.
• W2017024085 creator A5043087658 @default.
• W2017024085 creator A5056628915 @default.
• W2017024085 creator A5063314967 @default.
• W2017024085 date "2011-07-01" @default.
• W2017024085 modified "2023-09-27" @default.
• W2017024085 title "Radiosensitization of Human Cervical Cancer Cells by Inhibiting Ribonucleotide Reductase: Enhanced Radiation Response at Low-Dose Rates" @default.
• W2017024085 cites W1521417371 @default.
• W2017024085 cites W1572756764 @default.
• W2017024085 cites W1680634601 @default.
• W2017024085 cites W1964074099 @default.
• W2017024085 cites W1976558883 @default.
• W2017024085 cites W1976650039 @default.
• W2017024085 cites W2012914676 @default.
• W2017024085 cites W2013015071 @default.
• W2017024085 cites W2019227458 @default.
• W2017024085 cites W2029816972 @default.
• W2017024085 cites W2060455152 @default.
• W2017024085 cites W2061414735 @default.
• W2017024085 cites W2077871003 @default.
• W2017024085 cites W2081134321 @default.
• W2017024085 cites W2082702530 @default.
• W2017024085 cites W2085972813 @default.
• W2017024085 cites W2089876863 @default.
• W2017024085 cites W2100448174 @default.
• W2017024085 cites W2134393780 @default.
• W2017024085 cites W2163367614 @default.
• W2017024085 cites W2166913012 @default.
• W2017024085 cites W2315184862 @default.
• W2017024085 doi "https://doi.org/10.1016/j.ijrobp.2011.01.034" @default.
• W2017024085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3118909" @default.
• W2017024085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21470790" @default.
• W2017024085 hasPublicationYear "2011" @default.
• W2017024085 type Work @default.
• W2017024085 sameAs 2017024085 @default.
• W2017024085 citedByCount "24" @default.
• W2017024085 countsByYear W20170240852012 @default.
• W2017024085 countsByYear W20170240852013 @default.
• W2017024085 countsByYear W20170240852014 @default.
• W2017024085 countsByYear W20170240852015 @default.
• W2017024085 countsByYear W20170240852016 @default.
• W2017024085 countsByYear W20170240852017 @default.
• W2017024085 countsByYear W20170240852018 @default.
• W2017024085 countsByYear W20170240852020 @default.
• W2017024085 countsByYear W20170240852021 @default.
• W2017024085 crossrefType "journal-article" @default.
• W2017024085 hasAuthorship W2017024085A5016353084 @default.
• W2017024085 hasAuthorship W2017024085A5042269391 @default.
• W2017024085 hasAuthorship W2017024085A5043087658 @default.
• W2017024085 hasAuthorship W2017024085A5056628915 @default.
• W2017024085 hasAuthorship W2017024085A5063314967 @default.
• W2017024085 hasBestOaLocation W20170240852 @default.
• W2017024085 hasConcept C104292427 @default.
• W2017024085 hasConcept C104317684 @default.
• W2017024085 hasConcept C111337013 @default.
• W2017024085 hasConcept C117262875 @default.
• W2017024085 hasConcept C121332964 @default.
• W2017024085 hasConcept C121608353 @default.
• W2017024085 hasConcept C125118446 @default.
• W2017024085 hasConcept C126322002 @default.
• W2017024085 hasConcept C1491633281 @default.
• W2017024085 hasConcept C18231593 @default.
• W2017024085 hasConcept C185544564 @default.
• W2017024085 hasConcept C26114605 @default.
• W2017024085 hasConcept C2776428644 @default.
• W2017024085 hasConcept C29537977 @default.
• W2017024085 hasConcept C2989005 @default.
• W2017024085 hasConcept C4710235 @default.
• W2017024085 hasConcept C502942594 @default.
• W2017024085 hasConcept C509974204 @default.
• W2017024085 hasConcept C55493867 @default.
• W2017024085 hasConcept C71924100 @default.
• W2017024085 hasConcept C86803240 @default.
• W2017024085 hasConceptScore W2017024085C104292427 @default.
• W2017024085 hasConceptScore W2017024085C104317684 @default.
• W2017024085 hasConceptScore W2017024085C111337013 @default.
• W2017024085 hasConceptScore W2017024085C117262875 @default.
• W2017024085 hasConceptScore W2017024085C121332964 @default.
• W2017024085 hasConceptScore W2017024085C121608353 @default.
• W2017024085 hasConceptScore W2017024085C125118446 @default.
• W2017024085 hasConceptScore W2017024085C126322002 @default.
• W2017024085 hasConceptScore W2017024085C1491633281 @default.
• W2017024085 hasConceptScore W2017024085C18231593 @default.
• W2017024085 hasConceptScore W2017024085C185544564 @default.
• W2017024085 hasConceptScore W2017024085C26114605 @default.
• W2017024085 hasConceptScore W2017024085C2776428644 @default.
• W2017024085 hasConceptScore W2017024085C29537977 @default.
• W2017024085 hasConceptScore W2017024085C2989005 @default.
• W2017024085 hasConceptScore W2017024085C4710235 @default.
• W2017024085 hasConceptScore W2017024085C502942594 @default.
• W2017024085 hasConceptScore W2017024085C509974204 @default.
• W2017024085 hasConceptScore W2017024085C55493867 @default.
• W2017024085 hasConceptScore W2017024085C71924100 @default.
• W2017024085 hasConceptScore W2017024085C86803240 @default.
• W2017024085 hasIssue "4" @default.

• next